NASDAQ:MURA Mural Oncology (MURA) Stock Price, News & Analysis $3.15 -0.05 (-1.56%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.10▼$3.3150-Day Range$2.97▼$3.5552-Week Range$2.88▼$17.00Volume63,871 shsAverage Volume204,497 shsMarket Capitalization$53.31 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Mural Oncology alerts: Email Address Mural Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside344.4% Upside$14.00 Price TargetShort InterestHealthy2.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 3 Articles This WeekInsider TradingSelling Shares$43,821 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($7.54) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector396th out of 909 stocksPharmaceutical Preparations Industry178th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingMural Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMural Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Mural Oncology's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.95% of the float of Mural Oncology has been sold short.Short Interest Ratio / Days to CoverMural Oncology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mural Oncology has recently increased by 4.29%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMural Oncology does not currently pay a dividend.Dividend GrowthMural Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MURA. Previous Next 1.4 News and Social Media Coverage News SentimentMural Oncology has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mural Oncology this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for MURA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mural Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,821.00 in company stock.Percentage Held by InsidersOnly 0.06% of the stock of Mural Oncology is held by insiders.Percentage Held by Institutions80.21% of the stock of Mural Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mural Oncology's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Mural Oncology are expected to grow in the coming year, from ($7.54) to ($3.94) per share.Price to Book Value per Share RatioMural Oncology has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Mural Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Mural Oncology Stock (NASDAQ:MURA)Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Read More MURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MURA Stock News HeadlinesSeptember 6 at 3:52 AM | uk.news.yahoo.comArtist’s ‘wonderwall’ mural which honours town’s past and present unveiledSeptember 4 at 4:30 PM | globenewswire.comMural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 1, 2024 | msn.comA new play about Gloria Molina looks at a life in politics and the courage to look past the naysayersAugust 27, 2024 | globenewswire.comMural Oncology to Present at Two Upcoming Investor ConferencesAugust 18, 2024 | msn.comCinergy specials, Linkin Park tribute among this week's entertainmentAugust 16, 2024 | msn.comStriking Gordon Sparks mural appears on house near Plymouth Argyle to honour radio legendAugust 14, 2024 | msn.comPancreatic cancer cells ‘starved’ by novel treatment and keto diet – studySeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 14, 2024 | msn.comGordon Sparks mural honours late BBC broadcasterAugust 13, 2024 | msn.comPresident Biden jokes about Tulane's tuition during New Orleans visitAugust 13, 2024 | finanznachrichten.deMural Oncology, Inc.: Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline ProgressAugust 13, 2024 | msn.comHoda is 'shocked' by surprise birthday celebrations on TODAY: 'That meant the world'August 13, 2024 | globenewswire.comMural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline ProgressAugust 11, 2024 | msn.comFormer YouTube CEO Susan Wojcicki has died at 56August 11, 2024 | yahoo.comKingfisher mural dedicated to honor arts patron Sarah TurnerAugust 9, 2024 | msn.com'Speechless': Brockton 11-year-old cancer survivor gets a 'Stranger Things' room makeoverAugust 5, 2024 | msn.comThe Anthony Edwards 1 Low Returns with a “Mural” Colorway on Anthony Edwards DaySee More Headlines Receive MURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mural Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/06/2024Next Earnings (Estimated)12/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MURA Previous SymbolNASDAQ:MURA CUSIPN/A CIK1971543 Webwww.muraloncology.com Phone353-1-905-8020FaxN/AEmployees119Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+344.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-207,450,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.54% Return on Assets-83.48% Debt Debt-to-Equity RatioN/A Current Ratio8.65 Quick Ratio8.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.01 per share Price / Book0.26Miscellaneous Outstanding Shares16,924,000Free Float16,914,000Market Cap$53.31 million OptionableOptionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Caroline J. Loew Ph.D. (Age 53)President, CEO & Director Comp: $303.29kMr. Adam D. Cutler B.A. (Age 49)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $496.65kDr. Vicki L. Goodman M.D. (Age 53)Chief Medical Officer Comp: $578.34kMs. Maiken Keson-Brookes (Age 51)Chief Legal Officer Mr. Justin LevineHead of Human Resources & VP of Human ResourcesKey CompetitorsScilexNASDAQ:SCLXMolecular PartnersNASDAQ:MOLNMacroGenicsNASDAQ:MGNXGenfitNASDAQ:GNFTProcaps GroupNASDAQ:PROCView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 1,688,000 shares on 8/15/2024Ownership: 9.974%Point72 Asia Singapore Pte. Ltd.Bought 26,642 shares on 8/15/2024Ownership: 0.157%Squarepoint Ops LLCBought 167,644 shares on 8/14/2024Ownership: 0.991%Cubist Systematic Strategies LLCBought 31,243 shares on 8/14/2024Ownership: 0.185%Canada Pension Plan Investment BoardBought 22,360 shares on 8/13/2024Ownership: 0.132%View All Insider TransactionsView All Institutional Transactions MURA Stock Analysis - Frequently Asked Questions How have MURA shares performed this year? Mural Oncology's stock was trading at $5.92 on January 1st, 2024. Since then, MURA shares have decreased by 46.8% and is now trading at $3.15. View the best growth stocks for 2024 here. How were Mural Oncology's earnings last quarter? Mural Oncology plc (NASDAQ:MURA) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($1.90) by $0.04. Who are Mural Oncology's major shareholders? Top institutional investors of Mural Oncology include Armistice Capital LLC (9.97%), Acadian Asset Management LLC (1.88%), Primecap Management Co. CA (1.39%) and Renaissance Technologies LLC (1.37%). View institutional ownership trends. How do I buy shares of Mural Oncology? Shares of MURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MURA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MURA Stock Alerts